{"id":"W4387826320","doi":"10.1016/j.annonc.2023.09.739","title":"1261O Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Chemotherapy; Internal medicine; Oncology; Phases of clinical research; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006711326,0.0007034899,0.001365841,0.0001442663,0.0002629546,0.0009962023,0.000415371,0.0006452085,0.007752668],"category_scores_gemma":[0.0008739962,0.0002423571,0.001617109,0.0001704612,0.0004626356,0.00051606,0.0002724641,0.002302646,0.001240084],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007675601,"about_ca_system_score_gemma":0.0009305701,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001056964,"about_ca_topic_score_gemma":0.004802151,"domain_scores_codex":[0.9997851,0.000103537,0.000008349703,0.00004662806,0.00001486738,0.00004148942],"domain_scores_gemma":[0.9996564,0.00009595171,0.0000557275,0.00003341844,0.00001704272,0.0001413352],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.886712,0.003478213,0.002159196,0.001307373,0.002071842,0.00005689152,0.00006206241,0.001929078,0.007021673,0.000664174,0.009525685,0.08501189],"study_design_scores_gemma":[0.8739735,0.09672073,0.009402011,0.0003074872,0.002875092,0.0001549513,0.000062343,0.002130921,0.002032574,0.001196762,0.01109622,0.00004742629],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9635384,0.01168253,0.0009925072,0.002401119,0.001254698,0.001418948,0.004440645,0.0002476536,0.01402355],"genre_scores_gemma":[0.9717711,0.004103126,0.001659324,0.002692172,0.0004103492,0.001174467,0.004816325,0.00007010265,0.01330308],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007752668,"threshold_uncertainty_score":0.02593523,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1100220735061866,"score_gpt":0.4371958706070614,"score_spread":0.3271737971008747,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}